Figure 3 | Scientific Reports

Figure 3

From: A clinically relevant pulse treatment generates a bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax

Figure 3

LU-102 overcomes resistance in BPR cells. (a) Effect of a single agent LU-102 treatments. Cells were treated continuously with LU-102 for 48 h before viability was determined using Alamar Blue; in a parallel experiment, activity was measured with Proteasome Glo 2 h after treatment; n = 2. (b) Cells were treated with Btz for 1 h when it was replaced with 3 µM LU-102 for 48 h, when Alamar Blue assay was performed, n = 2–3. (c) Cells were treated with 1 µM Btz for 1 h and then allowed to recover in media in the presence or absence of 3 µM LU-102. Cell lysates were analyzed by westerns. Uncropped images are presented in Fig. S3b.

Back to article page